48 results on '"Houlihan CF"'
Search Results
2. Epidemiology and natural history of human papillomavirus around the time of sexual debut
- Author
-
Houlihan, CF
- Published
- 2015
- Full Text
- View/download PDF
3. Life threatening infections labelled swine flu.
- Author
-
Houlihan CF, Patel S, Price DA, Valappil M, and Schwab U
- Published
- 2010
- Full Text
- View/download PDF
4. Histopathological findings from the investigation of paediatric acute hepatitis of unknown aetiology, United Kingdom 2022.
- Author
-
Callaby H, McGuire E, Rajwal S, Stahlschmidt J, Hartley J, Brown RM, Deheragoda M, Quaglia A, Rampling T, Houlihan CF, Claire Gordon N, Brown CS, Simmons R, Samson A, Mandal S, Grammatikopoulos T, and Demirjian A
- Subjects
- Humans, Child, Liver pathology, Biopsy, Hepatitis pathology, Liver Transplantation, Liver Diseases pathology
- Abstract
In 2022, there were global reports of increased numbers of acute hepatitis not explained by hepatitis A-E virus infection in children. This manuscript summarises histopathology results from 20 patients in the United Kingdom who underwent liver transplant or had a liver biopsy as part of aetiological investigations. All available histopathological samples were reviewed centrally as part of the outbreak investigation. A working group comprised of infection specialists, hepatologists and histopathologists met virtually to review the cases, presentation, investigations and histopathology. All 20 liver samples had evidence of inflammation without significant interface activity, and submassive confluent pan-lobular or multilobular hepatocellular necrosis. Overall, the predominant histopathological findings were of acute nonspecific hepatitis with submassive hepatic necrosis and central vein perivenulitis and endothelitis. Histopathological findings were a poor indicator of aetiology., (© 2024 The Authors. Journal of Pediatric Gastroenterology and Nutrition published by Wiley Periodicals LLC on behalf of European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.)
- Published
- 2024
- Full Text
- View/download PDF
5. Monkeypox virus isolation from longitudinal samples from four patients to infer risk of onwards transmission: an interim analysis.
- Author
-
Callaby H, Emery K, Killip M, Rampling T, Richards KS, and Houlihan CF
- Subjects
- Animals, Chlorocebus aethiops, Monkeypox virus genetics, Polymerase Chain Reaction, Mpox (monkeypox) diagnosis
- Abstract
Monkeypox virus (mpxv) is a DNA virus in the Orthopoxvirus genus which causes Mpox (previously monkeypox). Symptoms include fever, lymphadenopathy and vesicular lesions. There is limited evidence for the duration of mpxv infectivity. This study used cell culture as a proxy for infectivity. Clinical samples from four patients with Mpox were inoculated into African green monkey kidney (Vero E6) cells and monitored for cytopathic effects (CPE). From one patient, infectious mpxv was recovered 25 days after illness onset. Infectious virus was not isolated from samples with an Orthopoxvirus polymerase chain reaction (PCR) Ct value over 31.0, nor from urine., (Crown Copyright © 2023. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
6. Imported rickettsial infections to the United Kingdom, 2015-2020.
- Author
-
Warrell CE, Osborne J, Nabarro L, Gibney B, Carter DP, Warner J, Houlihan CF, Brooks TJG, and Rampling T
- Subjects
- Humans, Doxycycline therapeutic use, Scrub Typhus diagnosis, Scrub Typhus epidemiology, Scrub Typhus microbiology, Typhus, Epidemic Louse-Borne, Rickettsia Infections diagnosis, Rickettsia Infections epidemiology, Rickettsia Infections microbiology, Rickettsia, Spotted Fever Group Rickettsiosis diagnosis, Spotted Fever Group Rickettsiosis epidemiology
- Abstract
Objective: The burden of imported rickettsial infection in the UK is not previously described. This retrospective review identifies rickettsial cases diagnosed at the national reference laboratory between 2015 and 2022., Methods: Samples testing positive for spotted fever group, typhus group, and scrub typhus IgG/IgM on acute and convalescent blood samples, and/or PCR on tissue/blood were categorized as suspected, confirmed or past infection., Results: 220 patients had rickettsioses, and the commonest import was acute spotted fever group infection (61%, 125/205), 54% (62/114) from South Africa. In acute typhus group cases, 60% (40/67) were from Southeast Asia. One patient with Rickettsia typhi bacteremia died. Scrub typhus group infections (5%, 10/205) were exclusively from Asia and the Western Pacific regions. Overall, 43% of confirmed cases (39/91) had not received doxycycline prior to results., Conclusions: Rickettsial infections are important and under-recognized causes of imported fever in the UK. Thorough history, examination, and timely treatment with doxycycline should be considered if there is suspicion of Rickettsia infection before testing., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
7. Comparison of new and emerging SARS-CoV-2 variant transmissibility through active contact testing. A comparative cross-sectional household seroprevalence study.
- Author
-
Gaskell KM, El Kheir N, Mirfendesky M, Rampling T, Marks M, Houlihan CF, Lemonge N, Bristowe H, Aslam S, Kyprianou D, Nastouli E, Goldblatt D, Fielding K, and Moore DAJ
- Subjects
- Humans, Seroepidemiologic Studies, Cross-Sectional Studies, Communicable Disease Control, SARS-CoV-2, COVID-19
- Abstract
Historically SARS-CoV-2 secondary attack rates (SAR) have been based on PCR positivity on screening symptomatic contacts; this misses transmission events and identifies only symptomatic contacts who are PCR positive at the time of sampling. We used serology to detect the relative transmissibility of Alpha Variant of Concern (VOC) to non-VOC SARS-CoV-2 to calculate household secondary attack rates. We identified index patients diagnosed with Alpha and non-VOC SARS-CoV-2 across two London Hospitals between November 2020 and January 2021 during a prolonged and well adhered national lockdown. We completed a household seroprevalence survey and found that 61.8% of non-VOC exposed household contacts were seropositive compared to 82.1% of Alpha exposed household contacts. The odds of infection doubled with exposure to an index diagnosed with Alpha. There was evidence of transmission events in almost all households. Our data strongly support that estimates of SAR should include serological data to improve accuracy and understanding., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Gaskell et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
8. Assessing spatiotemporal variability in SARS-CoV-2 infection risk for hospital workers using routinely-collected data.
- Author
-
Wilson-Aggarwal JK, Gotts N, Arnold K, Spyer MJ, Houlihan CF, Nastouli E, and Manley E
- Subjects
- Humans, Pandemics, Routinely Collected Health Data, SARS-CoV-2, Personnel, Hospital, Health Personnel, Hospitals, COVID-19 epidemiology
- Abstract
The COVID-19 pandemic has emphasised the need to rapidly assess infection risks for healthcare workers within the hospital environment. Using data from the first year of the pandemic, we investigated whether an individual's COVID-19 test result was associated with behavioural markers derived from routinely collected hospital data two weeks prior to a test. The temporal and spatial context of behaviours were important, with the highest risks of infection during the first wave, for staff in contact with a greater number of patients and those with greater levels of activity on floors handling the majority of COVID-19 patients. Infection risks were higher for BAME staff and individuals working more shifts. Night shifts presented higher risks of infection between waves of COVID-19 patients. Our results demonstrate the epidemiological relevance of deriving markers of staff behaviour from electronic records, which extend beyond COVID-19 with applications for other communicable diseases and in supporting pandemic preparedness., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Wilson-Aggarwal et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
9. AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
- Author
-
Levin MJ, Ustianowski A, Thomas S, Templeton A, Yuan Y, Seegobin S, Houlihan CF, Menendez-Perez I, Pollett S, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Ivanov S, Near KA, Sharbaugh A, Streicher K, Pangalos MN, and Esser MT
- Subjects
- Adult, Humans, SARS-CoV-2, Post-Exposure Prophylaxis, COVID-19 Vaccines, COVID-19 prevention & control
- Abstract
Background: This phase 3 trial assessed AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis against symptomatic coronavirus disease 2019 (COVID-19)., Methods: Adults without prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or COVID-19 vaccination were enrolled within 8 days of exposure to a SARS-CoV-2-infected individual and randomized 2:1 to a single 300-mg AZD7442 dose (one 1.5-mL intramuscular injection each of tixagevimab and cilgavimab) or placebo. Primary end points were safety and first post-dose SARS-CoV-2 reverse-transcription polymerase chain reaction (RT-PCR)-positive symptomatic COVID-19 event before day 183., Results: A total of 1121 participants were randomized and dosed (AZD7442, n = 749; placebo, n = 372). Median (range) follow-up was 49 (5-115) and 48 (20-113) days for AZD7442 and placebo, respectively. Adverse events occurred in 162 of 749 (21.6%) and 111 of 372 (29.8%) participants with AZD7442 and placebo, respectively, mostly mild/moderate. RT-PCR-positive symptomatic COVID-19 occurred in 23 of 749 (3.1%) and 17 of 372 (4.6%) AZD7442- and placebo-treated participants, respectively (relative risk reduction, 33.3%; 95% confidence interval [CI], -25.9 to 64.7; P = .21). In predefined subgroup analyses of 1073 (96%) participants who were SARS-CoV-2 RT-PCR-negative (n = 974, 87%) or missing an RT-PCR result (n = 99, 9%) at baseline, AZD7442 reduced RT-PCR-positive symptomatic COVID-19 by 73.2% (95% CI, 27.1 to 90.1) vs placebo., Conclusions: This study did not meet the primary efficacy end point of post-exposure prevention of symptomatic COVID-19. However, analysis of participants who were SARS-CoV-2 RT-PCR-negative or missing an RT-PCR result at baseline support a role for AZD7442 in preventing symptomatic COVID-19. Clinical Trials Registration. NCT04625972., Competing Interests: Potential conflicts of interest. M. J. L. reports research support from GSK, Johnson & Johnson, Moderna, and Novavax; consultancy for Dynavax, GSK, Merck & Co, Pfizer, and Seqirus; and participation on a data and safety monitoring board (DSMB)/advisory board for GSK. A. U. reports honoraria/speaker fees from Sanofi, Merck, Janssen, GSK, Roche, ViiV, and Gilead; advisory boards for Gilead, Merck, and ViiV/GSK; and participation on a DSMB for COV-Boost study, Flare study, and for Vicore. S. D. P. reports that the USU Infectious Diseases Clinical Research Program (IDCRP), a US Department of Defense institution, and HJF were funded under a cooperative research and development agreement to help conduct the STORM CHASER study, sponsored by AstraZeneca. The HJF, in support of the USU IDCRP, was also funded by the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense to augment the conduct of an unrelated phase 3 vaccine trial sponsored by AstraZeneca. Both of these trials were part of the US government COVID-19 response. M. T. E. reports patents planned, issued, or pending by AstraZeneca on AZD7442. P. G. reports consulting fees from Medicago and Takeda Vaccines as senior medical director; a leadership or fiduciary role as a full member of the Academy of Medicine in Rio de Janeiro, Brazil; and stock or stock options in Takeda Pharmaceuticals, AstraZeneca. All authors report medical writing assistance provided by Prime Global. S. T., A. T., Y. Y., S. S., R. H. A., R. B., K. D., P. G., E. J. K., G. C. K. W. K., S. I., K. A. N., A. S., K. S., M. N. P., and M. T. E. are employees of and hold or may hold stock in AstraZeneca. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2023
- Full Text
- View/download PDF
10. Detection of SARS-CoV-2 infection by saliva and nasopharyngeal sampling in frontline healthcare workers: An observational cohort study.
- Author
-
Walker NF, Byrne RL, Howard A, Nikolaou E, Farrar M, Glynn S, Cheliotis KS, Cubas Atienzar AI, Davies K, Reiné J, Rashid-Gardner Z, German EL, Solórzano C, Blandamer T, Hitchins L, Myerscough C, Gessner BD, Begier E, Collins AM, Beadsworth M, Todd S, Hill H, Houlihan CF, Nastouli E, Adams ER, Mitsi E, and Ferreira DM
- Subjects
- Humans, SARS-CoV-2, Cohort Studies, Retrospective Studies, State Medicine, Health Personnel, Specimen Handling, Nasopharynx, Saliva, COVID-19 diagnosis
- Abstract
Background: The SARS-CoV-2 pandemic has caused an unprecedented strain on healthcare systems worldwide, including the United Kingdom National Health Service (NHS). We conducted an observational cohort study of SARS-CoV-2 infection in frontline healthcare workers (HCW) working in an acute NHS Trust during the first wave of the pandemic, to answer emerging questions surrounding SARS-CoV-2 infection, diagnosis, transmission and control., Methods: Using self-collected weekly saliva and twice weekly combined oropharyngeal/nasopharyngeal (OP/NP) samples, in addition to self-assessed symptom profiles and isolation behaviours, we retrospectively compared SARS-CoV-2 detection by RT-qPCR of saliva and OP/NP samples. We report the association with contemporaneous symptoms and isolation behaviour., Results: Over a 12-week period from 30th March 2020, 40·0% (n = 34/85, 95% confidence interval 31·3-51·8%) HCW had evidence of SARS-CoV-2 infection by surveillance OP/NP swab and/or saliva sample. Symptoms were reported by 47·1% (n = 40) and self-isolation by 25·9% (n = 22) participants. Only 44.1% (n = 15/34) participants with SARS-CoV-2 infection reported any symptoms within 14 days of a positive result and only 29·4% (n = 10/34) reported self-isolation periods. Overall agreement between paired saliva and OP/NP swabs was 93·4% (n = 211/226 pairs) but rates of positive concordance were low. In paired samples with at least one positive result, 35·0% (n = 7/20) were positive exclusively by OP/NP swab, 40·0% (n = 8/20) exclusively by saliva and in only 25·0% (n = 5/20) were the OP/NP and saliva result both positive., Conclusions: HCW are a potential source of SARS-CoV-2 transmission in hospitals and symptom screening will identify the minority of infections. Without routine asymptomatic SARS-CoV-2 screening, it is likely that HCW with SARS-CoV-2 infection would continue to attend work. Saliva, in addition to OP/NP swab testing, facilitated ascertainment of symptomatic and asymptomatic SARS-CoV-2 infections. Combined saliva and OP/NP swab sampling would improve detection of SARS-CoV-2 for surveillance and is recommended for a high sensitivity strategy., Competing Interests: EB and BDG hold Pfizer stock as Pfizer employees. No other relationships or activities exist that could appear to have influenced the submitted work. Sources of grant funding are stated (see Financial Disclosures) and affiliations given for each author., (Copyright: © 2023 Walker et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
11. Investigating healthcare worker mobility and patient contacts within a UK hospital during the COVID-19 pandemic.
- Author
-
Wilson-Aggarwal JK, Gotts N, Wong WK, Liddington C, Knight S, Spyer MJ, Houlihan CF, Nastouli E, and Manley E
- Abstract
Background: Insights into behaviours relevant to the transmission of infections are extremely valuable for epidemiological investigations. Healthcare worker (HCW) mobility and patient contacts within the hospital can contribute to nosocomial outbreaks, yet data on these behaviours are often limited., Methods: Using electronic medical records and door access logs from a London teaching hospital during the COVID-19 pandemic, we derive indicators for HCW mobility and patient contacts at an aggregate level. We assess the spatial-temporal variations in HCW behaviour and, to demonstrate the utility of these behavioural markers, investigate changes in the indirect connectivity of patients (resulting from shared contacts with HCWs) and spatial connectivity of floors (owing to the movements of HCWs)., Results: Fluctuations in HCW mobility and patient contacts were identified during the pandemic, with the most prominent changes in behaviour on floors handling the majority of COVID-19 patients. The connectivity between floors was disrupted by the pandemic and, while this stabilised after the first wave, the interconnectivity of COVID-19 and non-COVID-19 wards always featured. Daily rates of indirect contact between patients provided evidence for reactive staff cohorting in response to the number of COVID-19 patients in the hospital., Conclusions: Routinely collected electronic records in the healthcare environment provide a means to rapidly assess and investigate behaviour change in the HCW population, and can support evidence based infection prevention and control activities. Integrating frameworks like ours into routine practice will empower decision makers and improve pandemic preparedness by providing tools to help curtail nosocomial outbreaks of communicable diseases., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
12. Neurological and psychiatric presentations associated with human monkeypox virus infection: A systematic review and meta-analysis.
- Author
-
Badenoch JB, Conti I, Rengasamy ER, Watson CJ, Butler M, Hussain Z, Carter B, Rooney AG, Zandi MS, Lewis G, David AS, Houlihan CF, Easton A, Michael BD, Kuppalli K, Nicholson TR, Pollak TA, and Rogers JP
- Abstract
Background: Neuropsychiatric presentations of monkeypox (MPX) infection have not been well characterised, despite evidence of nervous system involvement associated with the related smallpox infection., Methods: In this pre-registered (PROSPERO ID 336649) systematic review and meta-analysis, we searched MEDLINE, EMBASE, PsycINFO, AMED and the preprint server MedRxiv up to 31/05/2022. Any study design of humans infected with MPX that reported a neurological or psychiatric presentation was included. For eligible symptoms, we calculated a pooled prevalence using an inverse variance approach and corresponding 95% confidence intervals. The degree of variability that could be explained by between-study heterogeneity was assessed using the I
2 statistic. Risk of bias was assessed with the Newcastle Ottawa Scale and the Joanna Briggs Institute quality assessment tool., Findings: From 1705 unique studies, we extracted data on 19 eligible studies (1512 participants, 1031 with confirmed infection using CDC criteria or PCR testing) most of which were cohort studies and case series with no control groups. Study quality was generally moderate. Three clinical features were eligible for meta-analysis: seizure 2.7% (95% CI 0.7-10.2%, I2 0%), confusion 2.4% (95% CI 1.1-5.2%, I2 0%) and encephalitis 2.0% (95% 0.5-8.2%, I2 55.8%). Other frequently reported symptoms included myalgia, headache and fatigue, where heterogeneity was too high for estimation of pooled prevalences, possibly as a result of differences in viral clades and study methodology., Interpretation: There is preliminary evidence for a range of neuropsychiatric presentations including severe neurological complications (encephalitis and seizure) and nonspecific neurological features (confusion, headache and myalgia). There is less evidence regarding the psychiatric presentations or sequelae of MPX. This may warrant surveillance within the current MPX outbreak, with prospective longitudinal studies evaluating the mid- to long-term sequelae of the virus. Robust methods to evaluate the potential causality of MPX with these clinical features are required. More evidence is necessary to explain heterogeneity in prevalence estimates., Funding: UKRI/MRC (MR/V03605X/1), MRC-CSF (MR/V007181/1), MRC/AMED (MR/T028750/1) and the Wellcome Trust (102186/B/13/Z) and (102186/B/13/Z) and UCLH BRC., Competing Interests: All authors have completed ICMJE uniform disclosure forms and declare; GL is supported by the UCLH BRC, is funded by NIHR, and is TSC chair for NIHR study and Wellcome Clinical PhD funding for JPR. CW receives support from the Royal College of Psychiatrists Pathfinder Fellowship and the Association of British Neurologists' Bursary. AE is a recipient of various grants for The Encephalitis Society which she is chief executive of, she has received payment for speaking and presentations from Pfizer, UCB, Bavarian Nordics, Valneva, CSL Behring and Biomerieux. MZ was supported to attend the European Academy of Neurology 2022 Encephalitis Workshop and Eisai Dec 2019 one lecture honoraria. ZH was supported to attend meetings by the Royal College of Psychiatrists Foundation Fellowship. BDM is supported by the UKRI/MRC (MR/V03605X/1), the MRCCSF (MR/V007181/1), the MRC/AMED (MR/T028750/1) and the Wellcome Trust (102186/B/13/Z). No other relationships or activities that could appear to have influenced the submitted work., (© 2022 The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
13. Clinical features and management of human monkeypox: a retrospective observational study in the UK.
- Author
-
Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MB, Duncan CJ, Dunning J, Fletcher TE, Hunter ER, Jacobs M, Khoo SH, Newsholme W, Porter D, Porter RJ, Ratcliffe L, Schmid ML, Semple MG, Tunbridge AJ, Wingfield T, and Price NM
- Subjects
- Adult, Animals, Antiviral Agents therapeutic use, Child, Female, Humans, Male, Prospective Studies, Retrospective Studies, United Kingdom epidemiology, Mpox (monkeypox) diagnosis, Mpox (monkeypox) drug therapy, Mpox (monkeypox) epidemiology
- Abstract
Background: Cases of human monkeypox are rarely seen outside of west and central Africa. There are few data regarding viral kinetics or the duration of viral shedding and no licensed treatments. Two oral drugs, brincidofovir and tecovirimat, have been approved for treatment of smallpox and have demonstrated efficacy against monkeypox in animals. Our aim was to describe the longitudinal clinical course of monkeypox in a high-income setting, coupled with viral dynamics, and any adverse events related to novel antiviral therapies., Methods: In this retrospective observational study, we report the clinical features, longitudinal virological findings, and response to off-label antivirals in seven patients with monkeypox who were diagnosed in the UK between 2018 and 2021, identified through retrospective case-note review. This study included all patients who were managed in dedicated high consequence infectious diseases (HCID) centres in Liverpool, London, and Newcastle, coordinated via a national HCID network., Findings: We reviewed all cases since the inception of the HCID (airborne) network between Aug 15, 2018, and Sept 10, 2021, identifying seven patients. Of the seven patients, four were men and three were women. Three acquired monkeypox in the UK: one patient was a health-care worker who acquired the virus nosocomially, and one patient who acquired the virus abroad transmitted it to an adult and child within their household cluster. Notable disease features included viraemia, prolonged monkeypox virus DNA detection in upper respiratory tract swabs, reactive low mood, and one patient had a monkeypox virus PCR-positive deep tissue abscess. Five patients spent more than 3 weeks (range 22-39 days) in isolation due to prolonged PCR positivity. Three patients were treated with brincidofovir (200 mg once a week orally), all of whom developed elevated liver enzymes resulting in cessation of therapy. One patient was treated with tecovirimat (600 mg twice daily for 2 weeks orally), experienced no adverse effects, and had a shorter duration of viral shedding and illness (10 days hospitalisation) compared with the other six patients. One patient experienced a mild relapse 6 weeks after hospital discharge., Interpretation: Human monkeypox poses unique challenges, even to well resourced health-care systems with HCID networks. Prolonged upper respiratory tract viral DNA shedding after skin lesion resolution challenged current infection prevention and control guidance. There is an urgent need for prospective studies of antivirals for this disease., Funding: None., Competing Interests: Declaration of interests JD reports an unremunerated role on a Data Safety and Monitoring Board (DSMB) for an extended access programme for tecovirimat. MGS reports non-remunerated roles in a DSMB for Pfizer's mRNA vaccine programme, the UK Scientific Advisory Group for Emergencies, and New Emerging Respiratory Virus Threats Advisory Group; and reports chairing a Scientific Advisory Board and holding stock or stock options in Integrum Scientific LLC, Greensboro, NC, USA. SHK reports grants (unrelated to the current work) from ViiV, Merck, and Gilead Sciences; advisory board membership for ViiV and Merck; honoraria from ViiV; and being an unremunerated chair of a DSMB for a Gates Foundation-funded trial., (Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
14. Monkeypox: An old foe, with new challenges.
- Author
-
Bosworth A, Wakerley D, Houlihan CF, and Atabani SF
- Abstract
At first glance, a multi-country outbreak of monkeypox in 2022 seems unusual. However, the re-emergence and expansion of this viral disease beyond its endemicity in West and Central Africa had previously been predicted as a possible consequence of a decline in population immunity following smallpox eradication. Since the 13th of May 2022, cases of monkeypox have been reported in at least 28 WHO member states from within 4 regions (the Americans, European, Eastern Mediterranean and Western Pacific regions). This summary describes the multi-country outbreak to date, with an emphasis on patient demographics, common symptoms and signs, clinical management (including infection prevention measures) and clinical outcomes of the cases in the United Kingdom, which has so far reported the largest number of laboratory confirmed cases. The future implications of this outbreak, including preventative measures to curb the current outbreak, prevent future outbreaks and the likelihood of the disease becoming endemic in the UK are also discussed., (Crown Copyright © 2022 Published by Elsevier Ltd on behalf of The Healthcare Infection Society.)
- Published
- 2022
- Full Text
- View/download PDF
15. Amyloid processing in COVID-19-associated neurological syndromes.
- Author
-
Ziff OJ, Ashton NJ, Mehta PR, Brown R, Athauda D, Heaney J, Heslegrave AJ, Benedet AL, Blennow K, Checkley AM, Houlihan CF, Gauthier S, Rosa-Neto P, Fox NC, Schott JM, Zetterberg H, Benjamin LA, and Paterson RW
- Subjects
- Amyloid beta-Peptides metabolism, Amyloid beta-Protein Precursor cerebrospinal fluid, Biomarkers cerebrospinal fluid, Cohort Studies, Cross-Sectional Studies, Humans, Pilot Projects, Prospective Studies, SARS-CoV-2, Alzheimer Disease cerebrospinal fluid, Amyloidosis, COVID-19 complications
- Abstract
SARS-CoV-2 infection can damage the nervous system with multiple neurological manifestations described. However, there is limited understanding of the mechanisms underlying COVID-19 neurological injury. This is a cross-sectional exploratory prospective biomarker cohort study of 21 patients with COVID-19 neurological syndromes (Guillain-Barre Syndrome [GBS], encephalitis, encephalopathy, acute disseminated encephalomyelitis [ADEM], intracranial hypertension, and central pain syndrome) and 23 healthy COVID-19 negative controls. We measured cerebrospinal fluid (CSF) and serum biomarkers of amyloid processing, neuronal injury (neurofilament light), astrocyte activation (GFAp), and neuroinflammation (tissue necrosis factor [TNF] ɑ, interleukin [IL]-6, IL-1β, IL-8). Patients with COVID-19 neurological syndromes had significantly reduced CSF soluble amyloid precursor protein (sAPP)-ɑ (p = 0.004) and sAPPβ (p = 0.03) as well as amyloid β (Aβ) 40 (p = 5.2 × 10
-8 ), Aβ42 (p = 3.5 × 10-7 ), and Aβ42/Aβ40 ratio (p = 0.005) compared to controls. Patients with COVID-19 neurological syndromes showed significantly increased neurofilament light (NfL, p = 0.001) and this negatively correlated with sAPPɑ and sAPPβ. Conversely, GFAp was significantly reduced in COVID-19 neurological syndromes (p = 0.0001) and this positively correlated with sAPPɑ and sAPPβ. COVID-19 neurological patients also displayed significantly increased CSF proinflammatory cytokines and these negatively correlated with sAPPɑ and sAPPβ. A sensitivity analysis of COVID-19-associated GBS revealed a non-significant trend toward greater impairment of amyloid processing in COVID-19 central than peripheral neurological syndromes. This pilot study raises the possibility that patients with COVID-19-associated neurological syndromes exhibit impaired amyloid processing. Altered amyloid processing was linked to neuronal injury and neuroinflammation but reduced astrocyte activation., (© 2022 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.)- Published
- 2022
- Full Text
- View/download PDF
16. Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases.
- Author
-
Deakin CT, Cornish GH, Ng KW, Faulkner N, Bolland W, Hope J, Rosa A, Harvey R, Hussain S, Earl C, Jebson BR, Wilkinson MGLL, Marshall LR, O'Brien K, Rosser EC, Radziszewska A, Peckham H, Patel H, Heaney J, Rickman H, Paraskevopoulou S, Houlihan CF, Spyer MJ, Gamblin SJ, McCauley J, Nastouli E, Levin M, Cherepanov P, Ciurtin C, Wedderburn LR, and Kassiotis G
- Subjects
- Adolescent, Adult, Antibodies, Viral, Antibody Formation, Child, Humans, Immunoglobulin G, Nucleoproteins, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Systemic Inflammatory Response Syndrome, Autoimmune Diseases, COVID-19 complications, Coronavirus OC43, Human, Rheumatic Diseases
- Abstract
Background: Differences in humoral immunity to coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), between children and adults remain unexplained, and the effect of underlying immune dysfunction or suppression is unknown. Here, we sought to examine the antibody immune competence of children and adolescents with prevalent inflammatory rheumatic diseases, juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM), and juvenile systemic lupus erythematosus (JSLE) against the seasonal human coronavirus (HCoV)-OC43 that frequently infects this age group., Methods: Sera were collected from JIA (n = 118), JDM (n = 49), and JSLE (n = 30) patients and from healthy control (n = 54) children and adolescents prior to the coronavirus disease 19 (COVID-19) pandemic. We used sensitive flow-cytometry-based assays to determine titers of antibodies that reacted with the spike and nucleoprotein of HCoV-OC43 and cross-reacted with the spike and nucleoprotein of SARS-CoV-2, and we compared them with respective titers in sera from patients with multisystem inflammatory syndrome in children and adolescents (MIS-C)., Findings: Despite immune dysfunction and immunosuppressive treatment, JIA, JDM, and JSLE patients maintained comparable or stronger humoral responses than healthier peers, which was dominated by immunoglobulin G (IgG) antibodies to HCoV-OC43 spike, and harbored IgG antibodies that cross-reacted with SARS-CoV-2 spike. In contrast, responses to HCoV-OC43 and SARS-CoV-2 nucleoproteins exhibited delayed age-dependent class-switching and were not elevated in JIA, JDM, and JSLE patients, which argues against increased exposure., Conclusions: Consequently, autoimmune rheumatic diseases and their treatment were associated with a favorable ratio of spike to nucleoprotein antibodies., Funding: This work was supported by a Centre of Excellence Centre for Adolescent Rheumatology Versus Arthritis grant, 21593, UKRI funding reference MR/R013926/1, the Great Ormond Street Children's Charity, Cure JM Foundation, Myositis UK, Lupus UK, and the NIHR Biomedical Research Centres at GOSH and UCLH. This work was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK, the UK Medical Research Council, and the Wellcome Trust ., Competing Interests: The authors declare no competing interests., (© 2021 Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
17. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study.
- Author
-
Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, Scott R, Sconza R, Price J, Margaritis M, Bergstrom M, Spyer MJ, Miralhes PB, Grant P, Kirk S, Valerio C, Mangera Z, Prabhahar T, Moreno-Cuesta J, Arulkumaran N, Singer M, Shin GY, Sanchez E, Paraskevopoulou SM, Pillay D, McKendry RA, Mirfenderesky M, Houlihan CF, and Nastouli E
- Subjects
- Aged, Aged, 80 and over, Cohort Studies, Female, Humans, London, Male, Middle Aged, Phylogeny, United Kingdom, Viral Load, Virus Shedding, COVID-19 virology, Genome, Viral, SARS-CoV-2 genetics, Severity of Illness Index, Whole Genome Sequencing
- Abstract
Background: Emergence of variants with specific mutations in key epitopes in the spike protein of SARS-CoV-2 raises concerns pertinent to mass vaccination campaigns and use of monoclonal antibodies. We aimed to describe the emergence of the B.1.1.7 variant of concern (VOC), including virological characteristics and clinical severity in contemporaneous patients with and without the variant., Methods: In this cohort study, samples positive for SARS-CoV-2 on PCR that were collected from Nov 9, 2020, for patients acutely admitted to one of two hospitals on or before Dec 20, 2020, in London, UK, were sequenced and analysed for the presence of VOC-defining mutations. We fitted Poisson regression models to investigate the association between B.1.1.7 infection and severe disease (defined as point 6 or higher on the WHO ordinal scale within 14 days of symptoms or positive test) and death within 28 days of a positive test and did supplementary genomic analyses in a cohort of chronically shedding patients and in a cohort of remdesivir-treated patients. Viral load was compared by proxy, using PCR cycle threshold values and sequencing read depths., Findings: Of 496 patients with samples positive for SARS-CoV-2 on PCR and who met inclusion criteria, 341 had samples that could be sequenced. 198 (58%) of 341 had B.1.1.7 infection and 143 (42%) had non-B.1.1.7 infection. We found no evidence of an association between severe disease and death and lineage (B.1.1.7 vs non-B.1.1.7) in unadjusted analyses (prevalence ratio [PR] 0·97 [95% CI 0·72-1·31]), or in analyses adjusted for hospital, sex, age, comorbidities, and ethnicity (adjusted PR 1·02 [0·76-1·38]). We detected no B.1.1.7 VOC-defining mutations in 123 chronically shedding immunocompromised patients or in 32 remdesivir-treated patients. Viral load by proxy was higher in B.1.1.7 samples than in non-B.1.1.7 samples, as measured by cycle threshold value (mean 28·8 [SD 4·7] vs 32·0 [4·8]; p=0·0085) and genomic read depth (1280 [1004] vs 831 [682]; p=0·0011)., Interpretation: Emerging evidence exists of increased transmissibility of B.1.1.7, and we found increased virus load by proxy for B.1.1.7 in our data. We did not identify an association of the variant with severe disease in this hospitalised cohort., Funding: University College London Hospitals NHS Trust, University College London/University College London Hospitals NIHR Biomedical Research Centre, Engineering and Physical Sciences Research Council., Competing Interests: Declaration of interests MS reports funding support for at-cost development and manufacture of UCL-Ventura continuous positive airway pressure device for patients with COVID-19 from the UK Department of Health and Social Care, during the conduct of the study; grants and advisory board fees paid to institution research fund from NewB; grants from DSTL; advisory board and speaking fees paid into institutional research fund from Amormed, Biotest, General ElectricBaxter, Baxter, Roche, Bayer, and Shionogi; and grants from Critical Pressure and Apollo Therapeutics, outside the submitted work. All other authors declare no competing interests., (Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
18. Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study.
- Author
-
Benjamin LA, Paterson RW, Moll R, Pericleous C, Brown R, Mehta PR, Athauda D, Ziff OJ, Heaney J, Checkley AM, Houlihan CF, Chou M, Heslegrave AJ, Chandratheva A, Michael BD, Blennow K, Vivekanandam V, Foulkes A, Mummery CJ, Lunn MP, Keddie S, Spyer MJ, Mckinnon T, Hart M, Carletti F, Jäger HR, Manji H, Zandi MS, Werring DJ, Nastouli E, Simister R, Solomon T, Zetterberg H, Schott JM, Cohen H, and Efthymiou M
- Abstract
Background: A high prevalence of antiphospholipid antibodies has been reported in case series of patients with neurological manifestations and COVID-19; however, the pathogenicity of antiphospholipid antibodies in COVID-19 neurology remains unclear., Methods: This single-centre cross-sectional study included 106 adult patients: 30 hospitalised COVID-neurological cases, 47 non-neurological COVID-hospitalised controls, and 29 COVID-non-hospitalised controls, recruited between March and July 2020. We evaluated nine antiphospholipid antibodies: anticardiolipin antibodies [aCL] IgA, IgM, IgG; anti-beta-2 glycoprotein-1 [aβ
2 GPI] IgA, IgM, IgG; anti-phosphatidylserine/prothrombin [aPS/PT] IgM, IgG; and anti-domain I β2 GPI (aD1β2GPI) IgG., Findings: There was a high prevalence of antiphospholipid antibodies in the COVID-neurological (73.3%) and non-neurological COVID-hospitalised controls (76.6%) in contrast to the COVID-non-hospitalised controls (48.2%). aPS/PT IgG titres were significantly higher in the COVID-neurological group compared to both control groups ( p < 0.001). Moderate-high titre of aPS/PT IgG was found in 2 out of 3 (67%) patients with acute disseminated encephalomyelitis [ADEM]. aPS/PT IgG titres negatively correlated with oxygen requirement (FiO2 R =-0.15 p = 0.040) and was associated with venous thromboembolism ( p = 0.043). In contrast, aCL IgA ( p < 0.001) and IgG ( p < 0.001) was associated with non-neurological COVID-hospitalised controls compared to the other groups and correlated positively with d-dimer and creatinine but negatively with FiO2 ., Interpretation: Our findings show that aPS/PT IgG is associated with COVID-19-associated ADEM. In contrast, aCL IgA and IgG are seen much more frequently in non-neurological hospitalised patients with COVID-19. Characterisation of antiphospholipid antibody persistence and potential longitudinal clinical impact are required to guide appropriate management., Funding: This work is supported by UCL Queen Square Biomedical Research Centre (BRC) and Moorfields BRC grants (#560441 and #557595). LB is supported by a Wellcome Trust Fellowship (222102/Z/20/Z). RWP is supported by an Alzheimer's Association Clinician Scientist Fellowship (AACSF-20-685780) and the UK Dementia Research Institute. KB is supported by the Swedish Research Council (#2017-00915) and the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), and theUK Dementia Research Institute at UCL. BDM is supported by grants from the MRC/UKRI (MR/V007181/1), MRC (MR/T028750/1) and Wellcome (ISSF201902/3). MSZ, MH and RS are supported by the UCL/UCLH NIHR Biomedical Research Centre and MSZ is supported by Queen Square National Brain Appeal., Competing Interests: LAB reports grants from GlaxoSmithKline, grants from Wellcome Trust, outside the submitted work.; RWP reports grants from Neurofilament light consortium, personal fees from GE healthcare educational talk, outside the submitted work.; CP is co-inventor for a patented Domain I-based potential therapeutic for APS.; KB reports personal fees from Abcam (advisory board / consultant), personal fees from Axon (advisory board / consultant), personal fees from Biogen (advisory board / consultant), personal fees from Julius Clinical (data monitoring committee), personal fees from Lilly (advisory board / consultant), personal fees from MagQu (advisory board / consultant), personal fees from Novartis (data monitoring committee), personal fees from Roche Diagnostic (advisory board / consultant), personal fees from Siemens Healthineers (advisory board / consultant), outside the submitted work; and is co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.; CM reports personal fees from Biogen (sit on steering committee for aducanumab fees for time spent), personal fees from Roche (advisory board member fees for time spent), personal fees from Washington University (sit on therapeutic evalutation committee fees for time spent), outside the submitted work.; BS reports grants from UKRI/DHSC Global Effort on COVID-19 Research (Medical Research Council), non-financial support from UK National Institute for Health Research Global Health Research Group on Brain Infections, outside the submitted work.; MSZ reports receiving personal fees from UCB, for lecturing, outside the submitted work.; DJW reports personal fees from Bayer, personal fees from Alnylam, personal fees from Portola, outside the submitted work.; TS is on the Data Safety Monitoring Committee of Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children GSK3390107A (ChAd3 EBO-Z) vaccine from GSK, is a panel member of Covid-19 Vaccine Benefit Risk Expert Working Group, which assesses the benefits and risks of Covid-19 vaccines at the Medicines and Healthcare Regulatory Agency (UK), is a member of COVID-19 Therapeutics Advisory Panel at the United Kingdom Department of Health & Social Care, and is Chair/Co-Chair of theCOVID-19 Rapid Response and Rolling Funding Initiatives, which supported development of the Oxford-Astra Zeneca Covid-19 vaccine, at the National Institute for Health Research, outside the submitted work. In addition, TS has a patent Test for bacterial meningitis based on a blood test, filed for patent pending.; HZ reports personal fees from Wave (Advisory board / consultant), personal fees from Roche Diagnostics (Advisory board / consultant), personal fees from Biogen (Sponsored lecture), personal fees (Advisory board / consultant) from Samumed, Eisai, Denali, Nervgen, Roche Diagnostics, Siemens Healthineers, Pinteon Therapeutics, AZTherapies, CogRx, personal fees (Sponsored lecture) from Alzecure, Cellectricon, and Fujirebio, outside the submitted work; and is Co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.; JMS reports work support from National Institute for Health Research University College London Hospitals Biomedical Research Centre, during the conduct of the study; personal fees from Roche Pharmaceuticals (consulting), personal fees from Eli Lilly (consulting, lecturing), Drug Safety Monitoring Board at Axon Neuroscience, non-financial support from AVID Radiopharmaceuticals (PET tracer provision), consulting on educational activities from Biogen, personal fees from Merck (consulting), royalties from Oxford University Press, royalties from Henry Stewart Talks, grants from Wolfson Foundation, grants from Engineering and Physical Sciences Research Council (EP/J020990/1), grants from Medical Research Council Dementias Platform UK (MR/L023784/1), grants from Alzheimer's Research UK (ARUK-Network 2012-6-ICE; ARUK-PG2017-1946; ARUK-PG2017-1946), grants from Brain Research UK (UCC14191), grants from Weston Brain Institute (UB170045), grants from European Union's Horizon 2020 research and innovation programme (Grant 666,992), grants from British Heart Foundation (PG/17/90/33,415), personal fees from Alzheimer's Research UK (Chief Medical Officer), personal fees from UK Dementia Research Institute (Medical Advisor), outside the submitted work.; HC reports institutional research support and support to attend scientific meetings, and honoraria for lectures paid to UCLH charities from Bayer Healthcare, and consultancy fees paid to University College London Hospitals Charity from UCB Biopharma, outside the submitted work.; All other authors have nothing to disclose., (© 2021 The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
19. Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes.
- Author
-
Paterson RW, Benjamin LA, Mehta PR, Brown RL, Athauda D, Ashton NJ, Leckey CA, Ziff OJ, Heaney J, Heslegrave AJ, Benedet AL, Blennow K, Checkley AM, Houlihan CF, Mummery CJ, Lunn MP, Manji H, Zandi MS, Keddie S, Chou M, Vinayan Changaradil D, Solomon T, Keshavan A, Barker S, Jäger HR, Carletti F, Simister R, Werring DJ, Spyer MJ, Nastouli E, Gauthier S, Rosa-Neto P, Zetterberg H, and Schott JM
- Abstract
Preliminary pathological and biomarker data suggest that SARS-CoV-2 infection can damage the nervous system. To understand what, where and how damage occurs, we collected serum and CSF from patients with COVID-19 and characterized neurological syndromes involving the PNS and CNS ( n = 34). We measured biomarkers of neuronal damage and neuroinflammation, and compared these with non-neurological control groups, which included patients with ( n = 94) and without ( n = 24) COVID-19. We detected increased concentrations of neurofilament light, a dynamic biomarker of neuronal damage, in the CSF of those with CNS inflammation (encephalitis and acute disseminated encephalomyelitis) [14 800 pg/ml (400, 32 400)], compared to those with encephalopathy [1410 pg/ml (756, 1446)], peripheral syndromes (Guillain-Barré syndrome) [740 pg/ml (507, 881)] and controls [872 pg/ml (654, 1200)]. Serum neurofilament light levels were elevated across patients hospitalized with COVID-19, irrespective of neurological manifestations. There was not the usual close correlation between CSF and serum neurofilament light, suggesting serum neurofilament light elevation in the non-neurological patients may reflect peripheral nerve damage in response to severe illness. We did not find significantly elevated levels of serum neurofilament light in community cases of COVID-19 arguing against significant neurological damage. Glial fibrillary acidic protein, a marker of astrocytic activation, was not elevated in the CSF or serum of any group, suggesting astrocytic activation is not a major mediator of neuronal damage in COVID-19., (© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.)
- Published
- 2021
- Full Text
- View/download PDF
20. The effect of spike mutations on SARS-CoV-2 neutralization.
- Author
-
Rees-Spear C, Muir L, Griffith SA, Heaney J, Aldon Y, Snitselaar JL, Thomas P, Graham C, Seow J, Lee N, Rosa A, Roustan C, Houlihan CF, Sanders RW, Gupta RK, Cherepanov P, Stauss HJ, Nastouli E, Doores KJ, van Gils MJ, and McCoy LE
- Subjects
- Antibodies, Monoclonal genetics, Antibodies, Monoclonal immunology, Antibodies, Viral immunology, Antibody Formation, COVID-19 immunology, COVID-19 metabolism, COVID-19 Vaccines immunology, HEK293 Cells, Humans, Neutralization Tests methods, Point Mutation, Receptors, Virus genetics, Receptors, Virus metabolism, Spike Glycoprotein, Coronavirus immunology, Antibodies, Neutralizing immunology, COVID-19 virology, SARS-CoV-2 genetics, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus genetics
- Abstract
Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the viral entry protein, spike. Because new SARS-CoV-2 variants are emerging rapidly, as exemplified by the B.1.1.7, B.1.351, and P.1 lineages, it is critical to understand whether antibody responses induced by infection with the original SARS-CoV-2 virus or current vaccines remain effective. In this study, we evaluate neutralization of a series of mutated spike pseudotypes based on divergence from SARS-CoV and then compare neutralization of the B.1.1.7 spike pseudotype and individual mutations. Spike-specific monoclonal antibody neutralization is reduced dramatically; in contrast, polyclonal antibodies from individuals infected in early 2020 remain active against most mutated spike pseudotypes, but potency is reduced in a minority of samples. This work highlights that changes in SARS-CoV-2 spike can alter neutralization sensitivity and underlines the need for effective real-time monitoring of emerging mutations and their effect on vaccine efficacy., Competing Interests: Declaration of interests Amsterdam UMC submitted a patent application on SARS-CoV-2 monoclonal antibodies, some of which were used in this study., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
21. Nosocomial Transmission of Coronavirus Disease 2019: A Retrospective Study of 66 Hospital-acquired Cases in a London Teaching Hospital.
- Author
-
Rickman HM, Rampling T, Shaw K, Martinez-Garcia G, Hail L, Coen P, Shahmanesh M, Shin GY, Nastouli E, and Houlihan CF
- Subjects
- Disease Outbreaks, Hospitals, Teaching, Humans, London epidemiology, Retrospective Studies, SARS-CoV-2, COVID-19, Cross Infection epidemiology
- Abstract
Coronavirus disease 2019 (COVID-19) can cause deadly healthcare-associated outbreaks. In a major London teaching hospital, 66 of 435 (15%) COVID-19 inpatient cases between 2 March and 12 April 2020 were definitely or probably hospital-acquired, through varied transmission routes. The case fatality was 36%. Nosocomial infection rates fell following comprehensive infection prevention and control measures., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
22. Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy.
- Author
-
Balestrini S, Koepp MJ, Gandhi S, Rickman HM, Shin GY, Houlihan CF, Anders-Cannon J, Silvennoinen K, Xiao F, Zagaglia S, Hudgell K, Ziomek M, Haimes P, Sampson A, Parker A, Helen Cross J, Pardington R, Nastouli E, Swanton C, Sander JW, and Sisodiya SM
- Subjects
- Adult, Aged, Aged, 80 and over, COVID-19 therapy, Cohort Studies, Comorbidity, Epilepsy therapy, Female, Humans, Infection Control methods, Male, Middle Aged, Treatment Outcome, United Kingdom epidemiology, Young Adult, COVID-19 epidemiology, Epilepsy epidemiology, Infection Control trends, Long-Term Care trends, Residential Facilities trends
- Abstract
In this cohort study, we aim to compare outcomes from coronavirus disease 2019 (COVID-19) in people with severe epilepsy and other co-morbidities living in long-term care facilities which all implemented early preventative measures, but different levels of surveillance. During 25-week observation period (16 March-6 September 2020), we included 404 residents (118 children), and 1643 caregivers. We compare strategies for infection prevention, control, and containment, and related outcomes, across four UK long-term care facilities. Strategies included early on-site enhancement of preventative and infection control measures, early identification and isolation of symptomatic cases, contact tracing, mass surveillance of asymptomatic cases and contacts. We measured infection rate among vulnerable people living in the facilities and their caregivers, with asymptomatic and symptomatic cases, including fatality rate. We report 38 individuals (17 residents) who tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive, with outbreaks amongst residents in two facilities. At Chalfont Centre for Epilepsy (CCE), 10/98 residents tested positive: two symptomatic (one died), eight asymptomatic on weekly enhanced surveillance; 2/275 caregivers tested positive: one symptomatic, one asymptomatic. At St Elizabeth's (STE), 7/146 residents tested positive: four symptomatic (one died), one positive during hospital admission for symptoms unrelated to COVID-19, two asymptomatic on one-off testing of all 146 residents; 106/601 symptomatic caregivers were tested, 13 positive. In addition, during two cycles of systematically testing all asymptomatic carers, four tested positive. At The Meath (TM), 8/80 residents were symptomatic but none tested; 26/250 caregivers were tested, two positive. At Young Epilepsy (YE), 8/80 children were tested, all negative; 22/517 caregivers were tested, one positive. Infection outbreaks in long-term care facilities for vulnerable people with epilepsy can be quickly contained, but only if asymptomatic individuals are identified through enhanced surveillance at resident and caregiver level. We observed a low rate of morbidity and mortality, which confirmed that preventative measures with isolation of suspected and confirmed COVID-19 residents can reduce resident-to-resident and resident-to-caregiver transmission. Children and young adults appear to have lower infection rates. Even in people with epilepsy and multiple co-morbidities, we observed a high percentage of asymptomatic people suggesting that epilepsy-related factors (anti-seizure medications and seizures) do not necessarily lead to poor outcomes., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
23. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.
- Author
-
Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl C, Wrobel AG, Benton DJ, Roustan C, Bolland W, Thompson R, Agua-Doce A, Hobson P, Heaney J, Rickman H, Paraskevopoulou S, Houlihan CF, Thomson K, Sanchez E, Shin GY, Spyer MJ, Joshi D, O'Reilly N, Walker PA, Kjaer S, Riddell A, Moore C, Jebson BR, Wilkinson M, Marshall LR, Rosser EC, Radziszewska A, Peckham H, Ciurtin C, Wedderburn LR, Beale R, Swanton C, Gandhi S, Stockinger B, McCauley J, Gamblin SJ, McCoy LE, Cherepanov P, Nastouli E, and Kassiotis G
- Subjects
- Adult, Aged, Aged, 80 and over, Amino Acid Sequence, Animals, COVID-19 blood, Epitope Mapping, Female, HEK293 Cells, Humans, Immunoglobulin A blood, Immunoglobulin G blood, Immunoglobulin M blood, Male, Middle Aged, SARS-CoV-2 chemistry, Spike Glycoprotein, Coronavirus chemistry, Viral Zoonoses blood, Viral Zoonoses immunology, Young Adult, Antibodies, Viral blood, COVID-19 immunology, Immunity, Humoral, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus immunology
- Abstract
Zoonotic introduction of novel coronaviruses may encounter preexisting immunity in humans. Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, we detected preexisting humoral immunity. SARS-CoV-2 spike glycoprotein (S)-reactive antibodies were detectable using a flow cytometry-based method in SARS-CoV-2-uninfected individuals and were particularly prevalent in children and adolescents. They were predominantly of the immunoglobulin G (IgG) class and targeted the S2 subunit. By contrast, SARS-CoV-2 infection induced higher titers of SARS-CoV-2 S-reactive IgG antibodies targeting both the S1 and S2 subunits, and concomitant IgM and IgA antibodies, lasting throughout the observation period. SARS-CoV-2-uninfected donor sera exhibited specific neutralizing activity against SARS-CoV-2 and SARS-CoV-2 S pseudotypes. Distinguishing preexisting and de novo immunity will be critical for our understanding of susceptibility to and the natural course of SARS-CoV-2 infection., (Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)
- Published
- 2020
- Full Text
- View/download PDF
24. The complexities of SARS-CoV-2 serology.
- Author
-
Houlihan CF and Beale R
- Subjects
- Adaptive Immunity, Antibodies, Neutralizing blood, Antibodies, Viral blood, Asymptomatic Infections, COVID-19 blood, COVID-19 immunology, Coronavirus Nucleocapsid Proteins immunology, Humans, Phosphoproteins immunology, Prognosis, SARS-CoV-2 immunology, Sensitivity and Specificity, Spike Glycoprotein, Coronavirus immunology, COVID-19 diagnosis, COVID-19 Serological Testing methods, COVID-19 Serological Testing standards, SARS-CoV-2 isolation & purification
- Published
- 2020
- Full Text
- View/download PDF
25. A case of limbic encephalitis associated with asymptomatic COVID-19 infection.
- Author
-
Zambreanu L, Lightbody S, Bhandari M, Hoskote C, Kandil H, Houlihan CF, and Lunn MP
- Subjects
- Aged, COVID-19, Coronavirus Infections therapy, Female, Humans, Limbic Encephalitis therapy, Pandemics, Pneumonia, Viral therapy, SARS-CoV-2, Betacoronavirus, Coronavirus Infections complications, Coronavirus Infections diagnosis, Limbic Encephalitis diagnostic imaging, Limbic Encephalitis virology, Pneumonia, Viral complications, Pneumonia, Viral diagnosis
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2020
- Full Text
- View/download PDF
26. Author Correction: Scalable and robust SARS-CoV-2 testing in an academic center.
- Author
-
Aitken J, Ambrose K, Barrell S, Beale R, Bineva-Todd G, Biswas D, Byrne R, Caidan S, Cherepanov P, Churchward L, Clark G, Crawford M, Cubitt L, Dearing V, Earl C, Edwards A, Ekin C, Fidanis E, Gaiba A, Gamblin S, Gandhi S, Goldman J, Goldstone R, Grant PR, Greco M, Heaney J, Hindmarsh S, Houlihan CF, Howell M, Hubank M, Hughes D, Instrell R, Jackson D, Jamal-Hanjani M, Jiang M, Johnson M, Jones L, Kanu N, Kassiotis G, Kirk S, Kjaer S, Levett A, Levett L, Levi M, Lu WT, MacRae JI, Matthews J, McCoy LE, Moore C, Moore D, Nastouli E, Nicod J, Nightingale L, Olsen J, O'Reilly N, Pabari A, Papayannopoulos V, Patel N, Peat N, Pollitt M, Ratcliffe P, Reis e Sousa C, Rosa A, Rosenthal R, Roustan C, Rowan A, Shin GY, Snell DM, Song OR, Spyer MJ, Strange A, Swanton C, Turner JMA, Turner M, Wack A, Walker PA, Ward S, Wong WK, Wright J, and Wu M
- Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2020
- Full Text
- View/download PDF
27. Scalable and robust SARS-CoV-2 testing in an academic center.
- Author
-
Aitken J, Ambrose K, Barrell S, Beale R, Bineva-Todd G, Biswas D, Byrne R, Caidan S, Cherepanov P, Churchward L, Clark G, Crawford M, Cubitt L, Dearing V, Earl C, Edwards A, Ekin C, Fidanis E, Gaiba A, Gamblin S, Gandhi S, Goldman J, Goldstone R, Grant PR, Greco M, Heaney J, Hindmarsh S, Houlihan CF, Howell M, Hubank M, Hughes D, Instrell R, Jackson D, Jamal-Hanjani M, Jiang M, Johnson M, Jones L, Kanu N, Kassiotis G, Kirk S, Kjaer S, Levett A, Levett L, Levi M, Lu WT, MacRae JI, Matthews J, McCoy LE, Moore C, Moore D, Nastouli E, Nicod J, Nightingale L, Olsen J, O'Reilly N, Pabari A, Papayannopoulos V, Patel N, Peat N, Pollitt M, Ratcliffe P, Reis e Sousa C, Rosa A, Rosenthal R, Roustan C, Rowan A, Shin GY, Snell DM, Song OR, Spyer MJ, Strange A, Swanton C, Turner JMA, Turner M, Wack A, Walker PA, Ward S, Wong WK, Wright J, and Wu M
- Subjects
- Academies and Institutes, COVID-19 Testing, Coronavirus Infections diagnosis, Europe, Humans, Reverse Transcriptase Polymerase Chain Reaction, United Kingdom, Clinical Laboratory Techniques, Medical Laboratory Science organization & administration
- Published
- 2020
- Full Text
- View/download PDF
28. Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers.
- Author
-
Houlihan CF, Vora N, Byrne T, Lewer D, Kelly G, Heaney J, Gandhi S, Spyer MJ, Beale R, Cherepanov P, Moore D, Gilson R, Gamblin S, Kassiotis G, McCoy LE, Swanton C, Hayward A, and Nastouli E
- Subjects
- Adult, COVID-19, Coronavirus Infections transmission, Cross Infection transmission, Cross Infection virology, Humans, Infectious Disease Transmission, Patient-to-Professional, London, Occupational Exposure, Pandemics, Pneumonia, Viral transmission, Prospective Studies, Risk Assessment, SARS-CoV-2, Antibodies, Viral blood, Betacoronavirus immunology, Coronavirus Infections blood, Cross Infection blood, Health Personnel, Pneumonia, Viral blood, Seroconversion
- Published
- 2020
- Full Text
- View/download PDF
29. Human papillomavirus DNA detected in fingertip, oral and bathroom samples from unvaccinated adolescent girls in Tanzania.
- Author
-
Houlihan CF, Baisley K, Bravo IG, Pavón MA, Changalucha J, Kapiga S, De Sanjosé S, Ross DA, Hayes RJ, and Watson-Jones D
- Subjects
- Adolescent, Cross-Sectional Studies, Female, Humans, Papillomaviridae classification, Papillomaviridae isolation & purification, Papillomavirus Infections diagnosis, Prevalence, Tanzania, Toilet Facilities, Vagina virology, DNA, Viral genetics, Fingers virology, Mouth virology, Papillomaviridae genetics, Papillomavirus Infections virology
- Abstract
Objective: Human papillomavirus (HPV) DNA has been detected in vaginal samples from adolescent girls who report no previous sex and, in high-income settings, from fingertips, raising the possibility of non-sexual transmission. No such studies originate from East Africa which bears among the highest cervical cancer incidence and HPV prevalence worldwide. HPV-related oral cancer incidence is increasing, but oral HPV prevalence data from East Africa are limited. We aimed to describe the HPV DNA prevalence in genital and non-genital sites and in the bathroom of unvaccinated adolescent girls, and examine genotype concordance between sites., Methods: We nested a cross-sectional study of HPV in genital and extragenital sites within a cohort study of vaginal HPV acquisition. Unvaccinated girls age 16-18 years in Tanzania, who reported ever having had sex, were consented, enrolled and tested for the presence of HPV DNA in vaginal samples collected using self-administered swabs, oral samples collected using an oral rinse, and on fingertips and bathroom surfaces collected using a cytobrush., Results: Overall, 65 girls were enrolled and 23 (35%, 95% CI 23% to 47%) had detectable vaginal HPV. Adequate (β-globin positive) samples were collected from 36 girls' fingertips and HPV was detected in 7 (19%, 95% CI 6% to 33%). 63 girls provided adequate oral samples, 4 (6%, 95% CI 0% to 13%) of which had HPV DNA detected. In bathroom samples from 58 girls, 4 (7%, 95% CI 0% to 14%) had detectable HPV DNA. Of the 11 girls with extragenital HPV, six had the same genotype in >1 site., Conclusion: We found a high prevalence of HPV in non-genital sites in adolescent girls and in their bathrooms, in this region with a high cervical cancer incidence. Concordance of genotypes between sites supports the possibility of autoinoculation., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
30. Herpesvirus Infections of the Central Nervous System.
- Author
-
Bharucha T, Houlihan CF, and Breuer J
- Subjects
- Central Nervous System Viral Diseases drug therapy, Central Nervous System Viral Diseases prevention & control, Cytomegalovirus isolation & purification, Herpesviridae Infections drug therapy, Herpesviridae Infections prevention & control, Herpesvirus 3, Human isolation & purification, Herpesvirus 4, Human isolation & purification, Humans, Vaccination, Antiviral Agents therapeutic use, Central Nervous System Viral Diseases diagnosis, Herpesviridae Infections diagnosis
- Abstract
There are over 200 herpesvirus species, of which 10 affect humans. Each of these 10 herpesviruses has a unique clinical syndrome, but common to all is their ability to cause infection and pathology in the central nervous system. In this article, we discuss the epidemiology, clinical presentation, diagnostic modalities, treatment, sequelae, and availability of vaccination of each of the following herpesviruses: herpes simplex virus 1 and 2, varicella zoster virus, human cytomegalovirus, human herpesvirus 6A, 6B, and 7, Epstein-Barr virus, human herpesvirus 8, and simian herpesvirus B., Competing Interests: None of the authors have any conflicts of interest to declare., (Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.)
- Published
- 2019
- Full Text
- View/download PDF
31. Advances in molecular diagnostic testing for central nervous system infections.
- Author
-
Houlihan CF, Bharucha T, and Breuer J
- Subjects
- Bacteria chemistry, Bacteria classification, Bacteria genetics, Fungi chemistry, Fungi classification, Fungi genetics, Humans, Metagenomics methods, Metagenomics trends, Proteomics methods, Proteomics trends, Viruses chemistry, Viruses classification, Viruses genetics, Bacteria isolation & purification, Central Nervous System Infections diagnosis, Fungi isolation & purification, Molecular Diagnostic Techniques methods, Molecular Diagnostic Techniques trends, Viruses isolation & purification
- Abstract
Purpose of Review: Central nervous system (CNS) infections present an ongoing diagnostic challenge for clinicians, with an aetiological agent remaining unidentified in the majority of cases even in high-income settings. This review summarizes developments in a range of diagnostic methods published in the past 18 months., Recent Findings: Several commercial assays exist for the detection of viral, bacterial and fungal pathogens using single multiplex PCR. Multicentre validation of the Biofire FilmArray panel illustrated high sensitivity for bacterial and fungal pathogens, but poor results for Cryptococcus species detection. The development of microarray cards for bacterial CNS pathogens shows promise but requires further validation. Few developments have been made in proteomics and transcriptomics, contrasted with significant increase in the use of metagenomic (or unbiased) sequencing. Novel viruses causing CNS infection have been described using this technique but contamination, cost, expertise and turnaround time requirements remain restrictive. Finally, the development of Gene Xpert and Ultra has revolutionized tuberculosis meningitis diagnostics with newly released recommendations for their use from the WHO., Summary: Progress has been made in the clinical validation and international recommendation of PCR-based tests for CNS infections. Sequencing techniques present the most dynamic field, although significant ongoing challenges persist.
- Published
- 2019
- Full Text
- View/download PDF
32. New filovirus disease classification and nomenclature.
- Author
-
Kuhn JH, Adachi T, Adhikari NKJ, Arribas JR, Bah IE, Bausch DG, Bhadelia N, Borchert M, Brantsæter AB, Brett-Major DM, Burgess TH, Chertow DS, Chute CG, Cieslak TJ, Colebunders R, Crozier I, Davey RT, de Clerck H, Delgado R, Evans L, Fallah M, Fischer WA 2nd, Fletcher TE, Fowler RA, Grünewald T, Hall A, Hewlett A, Hoepelman AIM, Houlihan CF, Ippolito G, Jacob ST, Jacobs M, Jakob R, Jacquerioz FA, Kaiser L, Kalil AC, Kamara RF, Kapetshi J, Klenk HD, Kobinger G, Kortepeter MG, Kraft CS, Kratz T, Bosa HSK, Lado M, Lamontagne F, Lane HC, Lobel L, Lutwama J, Lyon GM 3rd, Massaquoi MBF, Massaquoi TA, Mehta AK, Makuma VM, Murthy S, Musoke TS, Muyembe-Tamfum JJ, Nakyeyune P, Nanclares C, Nanyunja M, Nsio-Mbeta J, O'Dempsey T, Pawęska JT, Peters CJ, Piot P, Rapp C, Renaud B, Ribner B, Sabeti PC, Schieffelin JS, Slenczka W, Soka MJ, Sprecher A, Strong J, Swanepoel R, Uyeki TM, van Herp M, Vetter P, Wohl DA, Wolf T, Wolz A, Wurie AH, and Yoti Z
- Subjects
- Filoviridae pathogenicity, Hemorrhagic Fever, Ebola classification, Humans, Filoviridae classification, Filoviridae Infections classification, World Health Organization
- Published
- 2019
- Full Text
- View/download PDF
33. Outbreak science: recent progress in the detection and response to outbreaks of infectious diseases.
- Author
-
Houlihan CF and Whitworth JA
- Subjects
- Communicable Disease Control, Communicable Diseases epidemiology, Humans, Disease Outbreaks, Epidemiologic Methods
- Abstract
The frequency of reported outbreaks of infectious diseases has increased over the past 3 decades, with predictions that this rise will continue. Outbreak response continues to follow nine basic principles: establish the presence of an outbreak, verify the diagnosis, make a case definition, find cases and contacts, conduct basic epidemiology, test hypotheses, institute control measures, communicate the situation and establish ongoing surveillance. Within each of these areas, significant advances have been made over the past 5 years using progress in digital, laboratory, epidemiology and anthropological equipment or techniques. Irrespective of these, future outbreaks of high-consequence are inevitable, and vigilance and preparation must continue in order to prevent significant mortality, morbidity and socio-economic crisis., (© Royal College of Physicians 2019. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
34. Use of Whole-Genome Sequencing in the Investigation of a Nosocomial Influenza Virus Outbreak.
- Author
-
Houlihan CF, Frampton D, Ferns RB, Raffle J, Grant P, Reidy M, Hail L, Thomson K, Mattes F, Kozlakidis Z, Pillay D, Hayward A, and Nastouli E
- Subjects
- Cross Infection epidemiology, Disease Outbreaks, Humans, Infection Control methods, Influenza, Human epidemiology, Molecular Epidemiology methods, Whole Genome Sequencing methods, Cross Infection virology, Influenza A virus genetics, Influenza, Human virology
- Abstract
Traditional epidemiological investigation of nosocomial transmission of influenza involves the identification of patients who have the same influenza virus type and who have overlapped in time and place. This method may misidentify transmission where it has not occurred or miss transmission when it has. We used influenza virus whole-genome sequencing (WGS) to investigate an outbreak of influenza A virus infection in a hematology/oncology ward and identified 2 separate introductions, one of which resulted in 5 additional infections and 79 bed-days lost. Results from WGS are becoming rapidly available and may supplement traditional infection control procedures in the investigation and management of nosocomial outbreaks.
- Published
- 2018
- Full Text
- View/download PDF
35. The Acceptability of Online Consent in a Self-Test Serosurvey of Responders to the 2014-2016 West African Ebola Outbreak.
- Author
-
McGowan CR, Houlihan CF, Kingori P, and Glynn JR
- Abstract
Online participation in research is used increasingly to recruit geographically dispersed populations. Obtaining online consent is convenient, yet we know little about the acceptability of this practice. We carried out a serostudy among personnel returning to the UK/Ireland following deployment to West Africa during the 2014-2016 Ebola epidemic. We used an online procedure for consenting returnees and designed a small descriptive study to understand: how much of the consent material they read, how informed they felt and if they preferred online to traditional face-to-face consent. Of 261 returnees, 111 (43 per cent) completed the consent survey. Participants indicated a high level of engagement with the consent materials, with 67 per cent reporting having read all and 20 per cent having read 'most' of the materials. All participants indicated feeling completely (78 per cent) or mostly (22 per cent) informed about the purpose, methods and intended uses of the research, as well as what participation was required and what risks were involved. Only three participants indicated a preference for face-to-face consent. Free-text comments suggested that online consent may be an acceptable modality for uncomplicated and low-risk studies. The study sample was largely composed of health professionals, suggesting acceptability of online consent within this population.
- Published
- 2017
- Full Text
- View/download PDF
36. Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virus.
- Author
-
Glynn JR, Bower H, Johnson S, Houlihan CF, Montesano C, Scott JT, Semple MG, Bangura MS, Kamara AJ, Kamara O, Mansaray SH, Sesay D, Turay C, Dicks S, Wadoum REG, Colizzi V, Checchi F, Samuel D, and Tedder RS
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Cross-Sectional Studies, Ebolavirus pathogenicity, Enzyme-Linked Immunosorbent Assay methods, Female, Glycoproteins blood, Hemorrhagic Fever, Ebola virology, Humans, Infant, Male, Middle Aged, Prevalence, Sensitivity and Specificity, Sierra Leone epidemiology, Survivors, Asymptomatic Infections epidemiology, Ebolavirus isolation & purification, Family Characteristics, Hemorrhagic Fever, Ebola epidemiology, Seroepidemiologic Studies
- Abstract
Background: The frequency of asymptomatic infection with Ebola virus is unclear: previous estimates vary and there is no standard test. Asymptomatic infection with Ebola virus could contribute to population immunity, reducing spread. If people with asymptomatic infection are infectious it could explain re-emergences of Ebola virus disease (EVD) without known contact., Methods: We validated a new oral fluid anti-glycoprotein IgG capture assay among survivors from Kerry Town Ebola Treatment Centre and controls from communities unaffected by EVD in Sierra Leone. We then assessed the seroprevalence of antibodies to Ebola virus in a cross-sectional study of household contacts of the survivors. All household members were interviewed. Two reactive tests were required for a positive result, with a third test to resolve any discrepancies., Findings: The assay had a specificity of 100% (95% CI 98·9-100; 339 of 339 controls tested negative) and sensitivity of 95·9% (89·8-98·9; 93 of 97 PCR-confirmed survivors tested positive). Of household contacts not diagnosed with EVD, 47·6% (229 of 481) had high level exposure (direct contact with a corpse, body fluids, or a case with diarrhoea, vomiting, or bleeding). Among the contacts, 12·0% (95% CI 6·1-20·4; 11 of 92) with symptoms at the time other household members had EVD, and 2·6% (1·2-4·7; 10 of 388) with no symptoms tested positive. Among asymptomatic contacts, seropositivity was weakly correlated with exposure level., Interpretation: This new highly specific and sensitive assay showed asymptomatic infection with Ebola virus was uncommon despite high exposure. The low prevalence suggests asymptomatic infection contributes little to herd immunity in Ebola, and even if infectious, would account for few transmissions., Funding: Wellcome Trust ERAES Programme, Save the Children., (Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
37. Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the West African Ebola epidemic 2014-2016: A cross-sectional study.
- Author
-
Houlihan CF, McGowan CR, Dicks S, Baguelin M, Moore DAJ, Mabey D, Roberts CH, Kumar A, Samuel D, Tedder R, and Glynn JR
- Subjects
- Adult, Africa, Western, Cross-Sectional Studies, Female, Hemorrhagic Fever, Ebola virology, Humans, Ireland epidemiology, Male, Middle Aged, Mouth virology, Prevalence, Travel, United Kingdom epidemiology, Antibodies, Viral blood, Ebolavirus isolation & purification, Epidemics, Health Personnel statistics & numerical data, Hemorrhagic Fever, Ebola epidemiology
- Abstract
Background: Healthcare and other front-line workers are at particular risk of infection with Ebola virus (EBOV). Despite the large-scale deployment of international responders, few cases of Ebola virus disease have been diagnosed in this group. Since asymptomatic or pauci-symptomatic infection has been described, it is plausible that infections have occurred in healthcare workers but have escaped being diagnosed. We aimed to assess the prevalence of asymptomatic or pauci-symptomatic infection, and of exposure events, among returned responders to the West African Ebola epidemic 2014-2016., Methods and Findings: We used snowball sampling to identify responders who had returned to the UK or Ireland, and used an online consent and questionnaire to determine their exposure to EBOV and their experience of illness. Oral fluid collection devices were sent and returned by post, and samples were tested using an EBOV IgG capture assay that detects IgG to Ebola glycoprotein. Blood was collected from returnees with reactive samples for further testing. Unexposed UK controls were also recruited. In all, 300 individuals consented, of whom 268 (89.3%) returned an oral fluid sample (OFS). The majority had worked in Sierra Leone in clinical, laboratory, research, and other roles. Fifty-three UK controls consented and provided samples using the same method. Of the returnees, 47 (17.5%) reported that they had had a possible EBOV exposure. Based on their free-text descriptions, using a published risk assessment method, we classified 43 (16%) as having had incidents with risk of Ebola transmission, including five intermediate-risk and one high-risk exposure. Of the returnees, 57 (21%) reported a febrile or diarrhoeal illness in West Africa or within 1 mo of return, of whom 40 (70%) were not tested at the time for EBOV infection. Of the 268 OFSs, 266 were unreactive. Two returnees, who did not experience an illness in West Africa or on return, had OFSs that were reactive on the EBOV IgG capture assay, with similar results on plasma. One individual had no further positive test results; the other had a positive result on a double-antigen bridging assay but not on a competitive assay or on an indirect EBOV IgG ELISA. All 53 controls had non-reactive OFSs. While the participants were not a random sample of returnees, the number participating was high., Conclusions: This is the first study, to our knowledge, of the prevalence of EBOV infection in international responders. More than 99% had clear negative results. Sera from two individuals had discordant results on the different assays; both were negative on the competitive assay, suggesting that prior infection was unlikely. The finding that a significant proportion experienced "near miss" exposure events, and that most of those who experienced symptoms did not get tested for EBOV at the time, suggests a need to review and standardise protocols for the management of possible exposure to EBOV, and for the management of illness, across organisations that deploy staff to outbreaks.
- Published
- 2017
- Full Text
- View/download PDF
38. Novel surveillance methods for the control of Ebola virus disease.
- Author
-
Houlihan CF, Youkee D, and Brown CS
- Subjects
- Africa, Western epidemiology, Hemorrhagic Fever, Ebola epidemiology, Humans, Disease Outbreaks prevention & control, Hemorrhagic Fever, Ebola prevention & control, Population Surveillance methods
- Abstract
The unprecedented scale of the 2013-2016 West African Ebola virus disease (EVD) outbreak was in a large part due to failings in surveillance: contacts of confirmed cases were not systematically identified, monitored and diagnosed early, and new cases appearing in previously unaffected communities were similarly not rapidly identified, diagnosed and isolated. Over the course of this epidemic, traditional surveillance methods were strengthened and novel methods introduced. The wealth of experience gained, and the systems introduced in West Africa, should be used in future EVD outbreaks, as well as for other communicable diseases in the region and beyond., (© The Author 2017. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
39. Rapid acquisition of HPV around the time of sexual debut in adolescent girls in Tanzania.
- Author
-
Houlihan CF, Baisley K, Bravo IG, Kapiga S, de Sanjosé S, Changalucha J, Ross DA, Hayes RJ, and Watson-Jones D
- Subjects
- Adolescent, Cohort Studies, Female, Genotype, Humans, Incidence, Kaplan-Meier Estimate, Regression Analysis, Risk Factors, Schools, Tanzania epidemiology, Time Factors, Alphapapillomavirus classification, Papillomavirus Infections epidemiology, Papillomavirus Vaccines administration & dosage, Sexual Behavior, Uterine Cervical Neoplasms prevention & control
- Abstract
Background: No reports exist on genotype-specific human papillomavirus (HPV) acquisition in girls after first sex in sub-Saharan Africa, despite high HPV prevalence and cervical cancer incidence., Methods: We followed 503 HP-unvaccinated girls aged 15-16 years in Mwanza, Tanzania, 3-monthly for 18 months with interviews and self-administered vaginal swabs. Swabs were tested for 13 higHRisk and 24 low-risk HPV genotypes. Incidence, clearance and duration of overall HPV and genotype-specific infections were calculated and associated factors evaluated., Results: A total of 106 participants reported first sex prior to enrolment (N = 29) or during follow-up (N = 77). One was HIV-positive at the final visit. The remaining 105 girls contributed 323 adequate specimens. Incidence of any new HPV genotype was 225/100 person-years (pys), and incidence of vaccine types HPV-6, -11, -16 and -18 were 12, 2, 2 and 7/100 pys, respectively. Reporting sex in the past 3 months and knowing the most recent sexual partner for a longer period before sex were associated with HPV acquisition. Median time from reported sexual debut to first HPVinfection was 5 months, and infection duration was 6 months., Conclusion: This is the first description of HPV acquisition after first sex in sub-Saharan Africa where the incidence of cervical cancer is amongst the highest in the world. HPV incidence was very high after first sex, including some vaccine genotypes, and infection duration was short. This very high HPV incidence may help explain high cervical cancer rates, and supports recommendations that the HPV vaccine should be given to girls before first sex., (© The Author 2016; Published by Oxford University Press on behalf of the International Epidemiological Association.)
- Published
- 2016
- Full Text
- View/download PDF
40. The Incidence of Human Papillomavirus in Tanzanian Adolescent Girls Before Reported Sexual Debut.
- Author
-
Houlihan CF, Baisley K, Bravo IG, Kapiga S, de Sanjosé S, Changalucha J, Ross DA, Hayes RJ, and Watson-Jones D
- Subjects
- Adolescent, Female, Humans, Incidence, Risk Factors, Tanzania epidemiology, Papillomaviridae isolation & purification, Papillomavirus Infections epidemiology, Sexual Behavior
- Abstract
Purpose: Acquisition of human papillomavirus (HPV) in women occurs predominantly through vaginal sex. However, HPV has been detected in girls reporting no previous sex. We aimed to determine incidence and risk factors for HPV acquisition in girls who report no previous sex in Tanzania, a country with high HPV prevalence and cervical cancer incidence., Methods: We followed 503 adolescent girls aged 15-16 years in Mwanza, Tanzania, with face-to-face interviews and self-administered vaginal swabs every 3 months for 18 months; 397 girls reported no sex before enrollment or during follow-up; of whom, 120 were randomly selected. Samples from enrollment, 6-, 12-, and 18-month visits were tested for 37 HPV genotypes. Incidence, clearance, point prevalence, and duration of any HPV and genotype-specific infections were calculated and associated factors were evaluated., Results: Of 120 girls who reported no previous sex, 119 were included, contributing 438 samples. HPV was detected in 51 (11.6%) samples. The overall incidence of new HPV infections was 29.4/100 person-years (95% confidence interval: 15.9-54.2). The point prevalence of vaccine types HPV-6,-11,-16, and -18 was .9%, .9%, 2.0%, and 0%, respectively. Spending a night away from home and using the Internet were associated with incident HPV, and reporting having seen a pornographic movie was inversely associated with HPV incidence., Conclusions: Incident HPV infections were detected frequently in adolescent girls who reported no previous sex over 18 months. This is likely to reflect under-reporting of sex. A low-point prevalence of HPV genotypes in licensed vaccines was seen, indicating that vaccination of these girls might still be effective., (Copyright © 2016 Society for Adolescent Health and Medicine. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
41. Authors' reply to Kremer and Van de Perre.
- Author
-
Beeching NJ, Fenech M, and Houlihan CF
- Subjects
- Humans, Hemorrhagic Fever, Ebola
- Published
- 2015
- Full Text
- View/download PDF
42. Being ready to treat Ebola virus disease patients.
- Author
-
Brett-Major DM, Jacob ST, Jacquerioz FA, Risi GF, Fischer WA, Kato Y, Houlihan CF, Crozier I, Bosa HK, Lawler JV, Adachi T, Hurley SK, Berry LE, Carlson JC, Button TC, McLellan SL, Shea BJ, Kuniyoshi GG, Ferri M, Murthy SG, Petrosillo N, Lamontagne F, Porembka DT, Schieffelin JS, Rubinson L, O'Dempsey T, Donovan SM, Bausch DG, Fowler RA, and Fletcher TE
- Subjects
- Africa, Western epidemiology, Delivery of Health Care organization & administration, Delivery of Health Care standards, Health Personnel psychology, Health Personnel standards, Hemorrhagic Fever, Ebola epidemiology, Hemorrhagic Fever, Ebola prevention & control, Humans, Patient Safety, Protective Clothing, Epidemics prevention & control, Hemorrhagic Fever, Ebola therapy
- Abstract
As the outbreak of Ebola virus disease (EVD) in West Africa continues, clinical preparedness is needed in countries at risk for EVD (e.g., United States) and more fully equipped and supported clinical teams in those countries with epidemic spread of EVD in Africa. Clinical staff must approach the patient with a very deliberate focus on providing effective care while assuring personal safety. To do this, both individual health care providers and health systems must improve EVD care. Although formal guidance toward these goals exists from the World Health Organization, Medecin Sans Frontières, the Centers for Disease Control and Prevention, and other groups, some of the most critical lessons come from personal experience. In this narrative, clinicians deployed by the World Health Organization into a wide range of clinical settings in West Africa distill key, practical considerations for working safely and effectively with patients with EVD., (© The American Society of Tropical Medicine and Hygiene.)
- Published
- 2015
- Full Text
- View/download PDF
43. Ebola virus disease.
- Author
-
Beeching NJ, Fenech M, and Houlihan CF
- Subjects
- Africa, Western epidemiology, Antiviral Agents therapeutic use, Communicable Disease Control organization & administration, Diagnosis, Differential, Disease Outbreaks prevention & control, Early Diagnosis, Ebola Vaccines, Fluid Therapy methods, Humans, Physical Examination methods, Prognosis, Protective Clothing, Risk Assessment methods, Hemorrhagic Fever, Ebola diagnosis, Hemorrhagic Fever, Ebola therapy, Hemorrhagic Fever, Ebola transmission
- Published
- 2014
- Full Text
- View/download PDF
44. Prevalence of human papillomavirus in adolescent girls before reported sexual debut.
- Author
-
Houlihan CF, de Sanjosé S, Baisley K, Changalucha J, Ross DA, Kapiga S, Godinez JM, Bozicevic I, Hayes RJ, and Watson-Jones D
- Subjects
- Adolescent, Female, Genotype, Humans, Hygiene, Interviews as Topic, Papillomaviridae genetics, Papillomavirus Infections virology, Prevalence, Sexual Behavior statistics & numerical data, Tanzania epidemiology, Vagina virology, Papillomavirus Infections epidemiology
- Abstract
Background: Human papillomavirus (HPV) vaccines are recommended for girls prior to sexual debut because they are most effective if administered before girls acquire HPV. Little research has been done on HPV prevalence in girls who report not having passed sexual debut in high HPV-prevalence countries., Methods: Using attendance registers of randomly selected primary schools in the Mwanza region of Tanzania, we enrolled girls aged 15-16 years who reported not having passed sexual debut. A face-to-face interview on sexual behavior and intravaginal practices, and a nurse-assisted self-administered vaginal swab were performed. Swabs were tested for 13 high-risk and 24 low-risk HPV genotypes., Results: HPV was detected in 40/474 (8.4%; 95% confidence interval [CI], 5.9-11.0) girls. Ten different high-risk and 21 different low-risk genotypes were detected. High-risk genotypes were detected in 5.3% (95% CI, 3.5-7.8). In multivariable analysis, only intravaginal cleansing (practiced by 20.9%) was associated with HPV detection (adjusted odds ratio = 2.19, 95% CI, 1.09-4.39)., Conclusion: This cohort of adolescent Tanzanian girls had a high HPV prevalence prior to self-reported sexual debut, and this was associated with intravaginal cleansing. This most likely reflects underreporting of sexual activity, and it is possible that intravaginal cleansing is a marker for unreported sexual debut or nonpenetrative sexual behaviors., (© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.)
- Published
- 2014
- Full Text
- View/download PDF
45. Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis.
- Author
-
Houlihan CF, Larke NL, Watson-Jones D, Smith-McCune KK, Shiboski S, Gravitt PE, Smith JS, Kuhn L, Wang C, and Hayes R
- Subjects
- Female, HIV Seropositivity transmission, Health Knowledge, Attitudes, Practice, Humans, Incidence, Male, Papillomavirus Infections prevention & control, Papillomavirus Infections transmission, Papillomavirus Infections virology, Risk Factors, Alphapapillomavirus, HIV Seropositivity epidemiology, Papillomavirus Infections epidemiology, Sexual Behavior statistics & numerical data
- Abstract
Objectives: Human papillomavirus (HPV), one of the commonest sexually transmitted infections, may be a cofactor in HIV acquisition. We systematically reviewed the evidence for an association of HPV infection with HIV acquisition in women, heterosexual men and men who have sex with men (MSM)., Design: : Systematic review and meta-analysis., Methods: Studies meeting inclusion criteria in Pubmed, Embase and conference abstracts up to 29 July 2011 were identified. Random effects meta-analyses were performed to calculate summary hazard ratios (HR). Publication bias and statistical heterogeneity were evaluated and population attributable fractions (PAFs) calculated., Results: Eight articles were included, with previously unpublished data from five authors. Seven studies found an association between prevalent HPV and HIV acquisition. Risk of HIV acquisition in women doubled with prevalent HPV infection with any genotype [HR = 2.06 (95% CI = 1.44-2.94), I = 0%], although adjustment for confounders was often inadequate. The effect was similar for high-risk [HR = 1.99 (95% CI = 1.54-2.56), I = 8.4%] and low-risk [HR = 2.01 (95% CI = 1.27-3.20), I = 0%] HPV genotypes with weak evidence of publication bias (P = 0.06). Two studies in men were identified: both showed an association between HPV infection and HIV acquisition. Unpublished data from one of two studies in women indicated an association between genotypes targeted by HPV vaccines and HIV acquisition. PAFs for HIV attributable to infection with any HPV genotype ranged between 21 and 37%., Conclusion: If further studies validate the association between HPV infection and HIV acquisition, HPV vaccines may reduce HIV incidence in high HPV prevalence populations, in addition to preventing cervical cancer. HIV surveillance studies during implementation of HPV vaccine programmes are warranted.
- Published
- 2012
- Full Text
- View/download PDF
46. Cohort profile: Hlabisa HIV treatment and care programme.
- Author
-
Houlihan CF, Bland RM, Mutevedzi PC, Lessells RJ, Ndirangu J, Thulare H, and Newell ML
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Data Collection, Databases, Factual, Female, HIV Infections diagnosis, HIV Infections epidemiology, Humans, Infant, Male, Population Surveillance, South Africa epidemiology, Antirheumatic Agents therapeutic use, HIV Infections drug therapy
- Published
- 2011
- Full Text
- View/download PDF
47. The tuberculosis challenge in a rural South African HIV programme.
- Author
-
Houlihan CF, Mutevedzi PC, Lessells RJ, Cooke GS, Tanser FC, and Newell ML
- Subjects
- AIDS-Related Opportunistic Infections mortality, Adolescent, Adult, CD4 Lymphocyte Count, Female, Humans, Incidence, Male, Prevalence, Risk Factors, Rural Population, Sex Factors, South Africa epidemiology, Tuberculosis mortality, Viral Load, Young Adult, AIDS-Related Opportunistic Infections epidemiology, HIV Infections complications, HIV Infections epidemiology, Tuberculosis epidemiology
- Abstract
Background: South Africa remains the country with the greatest burden of HIV-infected individuals and the second highest estimated TB incidence per capita worldwide. Within South Africa, KwaZulu-Natal has one of the highest rates of TB incidence and an emerging epidemic of drug-resistant tuberculosis., Methods: Review of records of consecutive HIV-infected people initiated onto ART between 1st January 2005 and 31st March 2006. Patients were screened for TB at initiation and incident episodes recorded. CD4 counts, viral loads and follow-up status were recorded; data was censored on 5th August 2008. Geographic cluster analysis was performed using spatial scanning., Results: 801 patients were initiated. TB prevalence was 25.3%, associated with lower CD4 (AHR 2.61 p = 0.01 for CD4 <50 cells/microl) and prior TB (AHR 1.58 p = 0.02). Incidence was 6.89 per 100 person-years from 81 cases over 1175 person-years analysis time and was highest in the first 3 months after ART initiation; associated with male sex and higher log HIV RNA. Prevalent and incident TB were significantly associated with mortality (OR 1.81 p = 0.01 and 2.02 p = 0.01 respectively). Incident TB was associated with a non-significant trend towards viral load >25 copies/ml (OR 1.75 p = 0.11). A low-risk cluster for incident TB was identified for patients living near the local hospital in the geospatial analysis., Conclusion: There is a large burden of TB in this population. Rate of incident TB stabilises at a rate higher than that of the overall population. These data highlight the need for greater research on strategies for active case finding in rural settings and the need to focus on strengthening primary health care.
- Published
- 2010
- Full Text
- View/download PDF
48. A/H1N1 flu pandemic. Life threatening infections labelled swine flu.
- Author
-
Houlihan CF, Patel S, Price DA, Valappil M, and Schwab U
- Subjects
- Adult, Child, Critical Illness, Diagnostic Errors, Humans, Bacterial Infections diagnosis, Disease Outbreaks, Influenza A Virus, H1N1 Subtype, Influenza, Human diagnosis, Malaria, Falciparum diagnosis
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.